Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05642780 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Nov 30, 2026 to Nov 30, 2027 Trial status: Recruiting to Active, Not Recruiting · Study sites: 51 to 48 · Collaborators: 4 to 5v6 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 51 to 48
    • Collaborators: 4 to 5

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Sep 30, 2025 to Nov 30, 2026 Enrollment target: 184 to 240 · Completion date: Nov 22, 2025 to Dec 31, 2027 · Eligibility criteria expanded, about 7 words · 1 morev5 Show 4 more changesShow less
    • Enrollment target: 184 to 240
    • Completion date: Nov 22, 2025 to Dec 31, 2027
    • Eligibility criteria expanded, about 7 words
    • Study arms: 4 to 5

    See this version in full on ClinicalTrials.gov ↗

  3. Primary endpoints: 2 to 3 Study sites: 3 to 51 · Collaborators expanded, about 14 wordsv4 Show 2 more changesShow less
    • Study sites: 3 to 51
    • Collaborators expanded, about 14 words

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 3 · Start date changed from estimate of Dec 23, 2022 to Jan 17, 2023v3 Show 2 more changesShow less
    • Study sites: 0 to 3
    • Start date changed from estimate of Dec 23, 2022 to Jan 17, 2023
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.
Trial Details
NCT Number NCT05642780
Lead Sponsor Klus Pharma Inc.
Collaborators: Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc., Clario
Conditions Solid Tumor
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov